Savara Shorts Ease but Options Turn Cautious Ahead of Binary Month

SVRA enters its most consequential stretch of the year with short sellers pulling back modestly, retail attention spiking, and options traders turning more defensive than at any point since late September.

Short interest has eased from the levels flagged in Monday's note but remains heavily elevated. At 21.1% of free float, the position is down from the 36%-plus reading cited a week ago, reflecting a combination of new float from the May equity financing and gradual short covering. The direction over the past month is still net higher, up 3.8%, though the weekly trend has turned slightly negative, off 1.2%. Critically, the borrow market is no longer providing shorts with any particular pressure. Availability has loosened dramatically: shares available to borrow now cover roughly 445% of the short interest, well above the 52-week low of 149% touched in late September. Cost to borrow is running at 0.54%, less than half what it was six weeks ago. The easy, cheap short position noted in the previous article remains intact.

Options positioning has shifted in a way that stands out. The put/call ratio has jumped to 0.44, nearly double where it sat every day from late September through mid-October, and almost 1.9 standard deviations above its 20-day mean of 0.20. For most of October the ratio ran below 0.15, meaning almost no hedging activity relative to calls. The sudden move into puts over the past two sessions suggests a fresh wave of protection-buying ahead of the 11 November earnings print and the pending FDA decision on Molbreevi. The 52-week range for the PCR spans 0.04 to 3.23, so this is nowhere near historical extremes, but the pace of the change in two days is the tell.

The Street remains firmly bullish despite the stock's continued slide. JP Morgan's initiation at Overweight with a $12 target, filed on 7 October, is the most recent and most significant analyst action. The consensus across the three covering analysts carries a buy rating and a mean target of $11.06, implying roughly 132% upside from the current $4.76. The bull case rests on FDA approval of Molbreevi for autoimmune pulmonary alveolar proteinosis, a confirmed patient pool of around 5,500, a resubmitted BLA with a stronger manufacturing partner, and $149.5 million in recent equity financing plus a $75 million royalty funding arrangement that provides runway through commercialisation. The bear case centres on the single-asset risk, the relatively small addressable market, and an approval timeline that has already slipped past original August guidance. With a price-to-book of 3.2 and deeply negative earnings and EBITDA multiples, the stock is priced entirely on binary optionality, not fundamentals.

One data point worth noting sits in the alt data. Wikipedia attention for Savara is running at a z-score of 6.5 against its own 90-day history, an extreme reading for a small-cap biotech. The dataset measures retail attention, not a revenue indicator, but a z-score at this level typically accompanies either a catalyst announcement or speculative positioning ahead of one. Given the proximity of both the FDA decision and earnings, the spike likely reflects the same binary awareness visible in options flow.

Activist positioning adds a structural layer to the ownership picture. Two holders are on the SEC Schedule 13D register: Bain Capital Life Sciences at 9.99% of the class (as last disclosed March 2025) and Growth Equity Opportunities 17, the New Enterprise Associates vehicle, at 12% (as last disclosed November 2025). Both are on the activist register, though stakes are event-driven disclosures around the 5% threshold and positions may have changed since. BlackRock added over 1.2 million shares in the quarter to September and Vanguard added a further 185,000, giving the passive flows a positive tilt even as the stock fell. Marshall Wace added 1.7 million shares as of June, the largest discretionary change among the top holders.

Prior earnings prints give a mixed read. The last four events show one-day moves of minus 5.4%, minus 0.5%, minus 3.0%, and plus 7.2%, with the positive reading coming on the May 2026 print, the only release in that set where the stock gained. The three-week window ahead compresses the FDA decision and the November earnings into the same narrow period. What to watch is whether short interest continues its modest unwind as that date approaches, or whether fresh borrowing resumes if the FDA process extends past November.